Leap Therapeutics, Inc. (LPTX) COO Purchases $6,441,813.21 in Stock

Leap Therapeutics, Inc. (NASDAQ:LPTX) COO Augustine Lawlor purchased 1,057,769 shares of Leap Therapeutics stock in a transaction dated Tuesday, November 14th. The shares were bought at an average cost of $6.09 per share, for a total transaction of $6,441,813.21. The purchase was disclosed in a legal filing with the SEC, which can be accessed through this link.

Shares of Leap Therapeutics, Inc. (LPTX) traded up $0.02 during mid-day trading on Thursday, hitting $6.00. 50,400 shares of the stock traded hands, compared to its average volume of 23,478. Leap Therapeutics, Inc. has a twelve month low of $4.90 and a twelve month high of $10.10.

Leap Therapeutics (NASDAQ:LPTX) last issued its quarterly earnings results on Monday, November 13th. The company reported ($0.73) EPS for the quarter, missing the consensus estimate of ($0.62) by ($0.11). research analysts forecast that Leap Therapeutics, Inc. will post -3.15 EPS for the current fiscal year.

ILLEGAL ACTIVITY WARNING: This news story was reported by Markets Daily and is the property of of Markets Daily. If you are reading this news story on another publication, it was illegally stolen and reposted in violation of United States and international copyright law. The legal version of this news story can be read at https://www.themarketsdaily.com/2017/11/16/leap-therapeutics-inc-lptx-coo-purchases-6441813-21-in-stock.html.

A hedge fund recently bought a new stake in Leap Therapeutics stock. Renaissance Technologies LLC bought a new position in Leap Therapeutics, Inc. (NASDAQ:LPTX) during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 45,445 shares of the company’s stock, valued at approximately $417,000. Renaissance Technologies LLC owned about 0.48% of Leap Therapeutics as of its most recent SEC filing. 0.81% of the stock is currently owned by institutional investors.

Separately, Zacks Investment Research cut shares of Leap Therapeutics from a “hold” rating to a “sell” rating in a research report on Tuesday, October 17th.

About Leap Therapeutics

Leap Therapeutics, Inc, formerly HealthCare Pharmaceuticals, Inc, is a clinical-stage biopharmaceutical company. The Company engages in acquiring and developing therapeutics in cancer biology. Its lead product candidates for use in clinical trials include TRX518 and DKN-01. DKN-01 is a monoclonal antibody targeting Dickkopf-related protein 1 (DKK1).

Receive News & Ratings for Leap Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Leap Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply